Date: Sat 10/09/2022
Optometrist Credits: 0.75 General credits
A lot is new in Age-related macular degeneration (AMD) with new treatments becoming available and imaging revealing more detail. New approaches to treating neovascular AMD (nAMD) will be reviewed, including faricimab, the latest drug to be approved for nAMD. A new era is upon us with the first treatments for geographic atrophy (GA) likely to be approved soon. These new strategies will be reviewed as well as current late-stage trials of interventions such as Pegetacoplan. Imaging OCT can reveal the earliest signs of atrophy, reticular pseudo drusen and eyes at higher risk of developing nAMD. These OCT signs will be discussed.